Intellia Therapeutics, Inc.
(NASDAQ : NTLA)

( )
NTLA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$796.69m
AMGNAmgen Inc.
-0.76%185.501.2%$630.51m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$497.34m
BIIBBiogen Inc.
-4.17%321.171.3%$426.56m
ILMNIllumina, Inc.
-1.77%296.883.5%$314.34m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$301.49m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$262.15m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$232.43m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$150.79m
AAgilent Technologies, Inc.
-0.83%77.911.6%$143.97m
EXASExact Sciences Corporation
-0.42%83.2825.3%$128.91m
INCYIncyte Corporation
-0.49%83.332.5%$114.75m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$107.63m
EXELExelixis, Inc.
-0.09%21.226.4%$83.96m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$78.49m

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.